Clinical Trials on Consent Forms in Japan

Total 26 results

UCB Japan Co. Ltd.
Parexel

Completed

Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures

Epilepsy | Partial-onset Seizures

Japan
Biogen

Recruiting

A Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)

Relapsing Forms of Multiple Sclerosis

China, Japan
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor

Gastric Cancer | Metaplasia | Stage I Gastric Cancer | Initial-onset Gastric Cancer

Japan
UCB Japan Co. Ltd.

Completed

A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures

Epilepsy | Partial-onset Seizures

Japan
UCB Japan Co. Ltd.

Completed

An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures

Epilepsy | Partial Onset Seizures

Japan
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD

Adult Onset Still's Disease

Japan
Eisai Co., Ltd.

Completed

Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)

Partial Onset Seizures

Japan, Korea, Republic of
UCB Japan Co. Ltd.

Completed

An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy

Epilepsy | Partial Onset Seizures

Japan
Swedish Orphan Biovitrum
CMIC Co, Ltd. Japan

Recruiting

A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)

Still's Disease, Adult-Onset | Still's Disease, Juvenile Onset

Japan
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures

Partial Onset Seizures

Japan
Alexion Pharmaceuticals, Inc.

Completed

A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)

Myasthenia Gravis | Myasthenia Gravis, Generalized | Myasthenia Gravis, Juvenile Form

United States, Japan, Netherlands
Eli Lilly and Company

Active, not recruiting

A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS

Aicardi Goutieres Syndrome | Nakajo-Nishimura Syndrome | Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome | STING-Associated Vasculopathy With Onset in Infancy

Japan
Nobelpharma

Completed

Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures

Partial Onset Seizures

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase

Familial Cold Autoinflammatory Syndrome | Muckle-Wells Syndrome | Neonatal Onset Multisystem Inflammatory Disease | Cryopyrin-associated Periodic Syndromes

Japan
Sound Wave Innovation CO., LTD.

Recruiting

A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease

Alzheimer Disease, Early Onset

Japan
UCB Pharma SA
UCB Japan Co. Ltd.

Completed

A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures

Epilepsy | Partial Onset Seizures

China, Japan
UCB Pharma SA
UCB Japan Co. Ltd.

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures

Epilepsy | Partial-onset Seizures

China, Japan
Eisai Co., Ltd.

Completed

A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures

Partial-onset Seizures

Korea, Republic of, Japan, Australia, China, Malaysia, Taiwan, Thailand
Eisai Inc.

Completed

Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Partial-Onset or Primary Generalized Tonic-Clonic Seizures

Canada, France, Italy, Korea, Republic of, Spain, United States, Belgium, Czechia, Hungary, Japan, Latvia, Poland
Amicus Therapeutics

Recruiting

ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

Pompe Disease (Late-onset)

United States, Japan, Australia, Taiwan, Canada
UCB Biopharma SRL

Terminated

A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy (DUET)

Drug-Resistant Epilepsy | Focal-Onset Seizures

United States, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerlan... and more
UCB Biopharma SRL

Terminated

Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

Drug-Resistant Epilepsy | Focal-Onset Seizures

United States, Australia, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Lithuania, Mexico, Poland, Romania, Serbia, Slovakia, Spain, Turk... and more
UCB Biopharma S.P.R.L.

Completed

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy (ARISE)

Focal-Onset Seizures | Drug-resistant Epilepsy

United States, Australia, Belgium, Bulgaria, Canada, Czechia, France, Germany, Hungary, Italy, Japan, Lithuania, Mexico, Poland, Portugal, Slovakia, Spain, Turkey, United Kingdom
Bristol-Myers Squibb

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1)

Alzheimer Disease, Early Onset

United States, Australia, Belgium, Canada, France, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, United Kingdom
Amicus Therapeutics

Active, not recruiting

A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD

Pompe Disease (Late-onset)

United States, Germany, Taiwan, Belgium, Australia, Slovenia, Spain, Netherlands, Hungary, Japan, Austria, United Kingdom, France, Argentina, Canada, Sweden, Denmark, New Zealand, Greece, Korea, Republic of, Bosnia and Herzegovina, Ita... and more
Amicus Therapeutics

Completed

A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease (PROPEL)

Pompe Disease (Late-onset)

United States, Australia, Korea, Republic of, Japan, Taiwan, Belgium, Slovenia, New Zealand, United Kingdom, France, Argentina, Canada, Spain, Bosnia and Herzegovina, Germany, Sweden, Hungary, Austria, Bulgaria, Denmark, Greece, I... and more

Clinical Trials on Consent Forms in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations